Corriente Advisors, LLC Buys TFF Pharmaceuticals Inc, Reata Pharmaceuticals Inc, Cue Biopharma Inc, Sells Sonos Inc, uniQure NV, Ocular Therapeutix Inc

• New Purchases: TFFP, BYND, SPCE, VFF, DDOG, AXGT, ROKU, CMRX,
• Added Positions: RETA, CUE, CRDF, APTO, DMAC, MAXR, REPL,
• Sold Out: SONO, QURE, OCUL, CLDX, TSLA, ARWR, PAAS, PIRS, RWT,

For the details of Corriente Advisors, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/corriente+advisors%2C+llc/current-portfolio/portfolio

1. Maxar Technologies Inc (MAXR) - 1,972,061 shares, 25.23% of the total portfolio. Shares added by 3.79%
2. Reata Pharmaceuticals Inc (RETA) - 300,000 shares, 14.99% of the total portfolio. Shares added by 103.39%
3. Cue Biopharma Inc (CUE) - 1,437,445 shares, 11.10% of the total portfolio. Shares added by 117.80%
4. Aptose Biosciences Inc (APTO) - 3,430,000 shares, 10.56% of the total portfolio. Shares added by 23.77%
5. TFF Pharmaceuticals Inc (TFFP) - 1,058,823 shares, 10.03% of the total portfolio. New Position

Corriente Advisors, LLC initiated holding in TFF Pharmaceuticals Inc. The purchase prices were between $5.86 and $18.47, with an estimated average price of $11.23. The stock is now traded at around $14.06. The impact to a portfolio due to this purchase was 10.03%. The holding were 1,058,823 shares as of .

Corriente Advisors, LLC initiated holding in Beyond Meat Inc. The purchase prices were between $123.32 and $166.06, with an estimated average price of $135.38. The stock is now traded at around $146.35. The impact to a portfolio due to this purchase was 2.98%. The holding were 35,000 shares as of .

Corriente Advisors, LLC initiated holding in Virgin Galactic Holdings Inc. The purchase prices were between $15.73 and $25.54, with an estimated average price of $18.89. The stock is now traded at around $18.45. The impact to a portfolio due to this purchase was 2.47%. The holding were 250,000 shares as of .

Corriente Advisors, LLC initiated holding in Village Farms International Inc. The purchase prices were between $4.58 and $6.4, with an estimated average price of $5.48. The stock is now traded at around $5.28. The impact to a portfolio due to this purchase was 2.22%. The holding were 943,396 shares as of .

Corriente Advisors, LLC initiated holding in Datadog Inc. The purchase prices were between $75.28 and $102.16, with an estimated average price of $86.97. The stock is now traded at around $90.10. The impact to a portfolio due to this purchase was 2.1%. The holding were 40,000 shares as of .

Corriente Advisors, LLC initiated holding in Axovant Gene Therapies Ltd. The purchase prices were between $2.68 and $4.93, with an estimated average price of $3.29. The stock is now traded at around $1.94. The impact to a portfolio due to this purchase was 2.07%. The holding were 875,000 shares as of .

Corriente Advisors, LLC added to a holding in Reata Pharmaceuticals Inc by 103.39%. The purchase prices were between $93.53 and $163.34, with an estimated average price of $125.03. The stock is now traded at around $121.75. The impact to a portfolio due to this purchase was 7.62%. The holding were 300,000 shares as of .

Corriente Advisors, LLC added to a holding in Cue Biopharma Inc by 117.80%. The purchase prices were between $15.05 and $23.54, with an estimated average price of $19.21. The stock is now traded at around $11.30. The impact to a portfolio due to this purchase was 6%. The holding were 1,437,445 shares as of .

Corriente Advisors, LLC added to a holding in Cardiff Oncology Inc by 424.92%. The purchase prices were between $4.25 and $14.19, with an estimated average price of $6.56. The stock is now traded at around $16.61. The impact to a portfolio due to this purchase was 5.36%. The holding were 910,000 shares as of .

Corriente Advisors, LLC added to a holding in Aptose Biosciences Inc by 23.77%. The purchase prices were between $4.82 and $6.5, with an estimated average price of $5.55. The stock is now traded at around $4.63. The impact to a portfolio due to this purchase was 2.03%. The holding were 3,430,000 shares as of .

Corriente Advisors, LLC added to a holding in DiaMedica Therapeutics Inc by 262.74%. The purchase prices were between $3.91 and $7.15, with an estimated average price of $5.3. The stock is now traded at around $4.58. The impact to a portfolio due to this purchase was 1.15%. The holding were 730,000 shares as of .

Corriente Advisors, LLC sold out a holding in Sonos Inc. The sale prices were between $12.76 and $17.5, with an estimated average price of $14.71.

Corriente Advisors, LLC sold out a holding in uniQure NV. The sale prices were between $35.98 and $47.66, with an estimated average price of $40.99.

Corriente Advisors, LLC sold out a holding in Ocular Therapeutix Inc. The sale prices were between $7.36 and $9.87, with an estimated average price of $8.29.

Corriente Advisors, LLC sold out a holding in Celldex Therapeutics Inc. The sale prices were between $9.65 and $15.19, with an estimated average price of $11.71.

Corriente Advisors, LLC sold out a holding in Tesla Inc. The sale prices were between $223.93 and $498.32, with an estimated average price of $353.47.

Corriente Advisors, LLC sold out a holding in Arrowhead Pharmaceuticals Inc. The sale prices were between $33.21 and $51.27, with an estimated average price of $43.06.